Valdemir Melechco Carvalho

Valdemir Melechco Carvalho

Auto-generated profile, based on publicly available information

Valdemir Melechco Carvalho

Division of Research and Development, Fleury Group, Av. Morumbi, 8860 - Jardim das Acácias, São Paulo, São Paulo, 04580-060, Brazil

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KCKarina Helena Morais Cardozo
Karina Helena Morais Cardozo
ALAdriana Lebkuchen
Adriana Lebkuchen
GOGuilherme Gonçalves Okai
Guilherme Gonçalves Okai
RSRodrigo Andrade Schuch
Rodrigo Andrade Schuch
LVLuciana Godoy Viana
Luciana Godoy Viana
VCValdemir Melechco Carvalho
Valdemir Melechco Carvalho
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pressing public health systems around the world, and large population testing is a key step to control this pandemic disease. Here, we develop a high-throughput targeted proteomics assay to detect SARS-CoV-2 nucleoprotein peptides directly from nasopharyngeal and oropharyngeal swabs. A modified magnetic particle-based proteomics approach implemented on a robotic liquid handler enables fully automated preparation of 96 samples within 4 hours. A TFC-MS system allows multiplexed analysis of 4 samples within 10 min, enabling the processing of more than 500 samples per day. We validate this method qualitatively (Tier 3) and quantitatively (Tier 1) using 985 specimens previously analyzed by real-time RT-PCR, and detect up to 84% of the positive cases with up to 97% specificity. The presented strategy has high sample stability and should be considered as an option for SARS-CoV-2 testing in large populations.

19 January 2022 in Chest
Verified
Journal Article
Closed access
SGSara Q.C. Giampá
Sara Q.C. Giampá
SFSofia F. Furlan
Sofia F. Furlan
LFLunara S. Freitas
Lunara S. Freitas
TMThiago A. Macedo
Thiago A. Macedo
ALAdriana Lebkuchen
Adriana Lebkuchen
LDLuciano F. Drager
Luciano F. Drager


18 December 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
APAna Maria Passos-Castilho
Ana Maria Passos-Castilho
VCValdemir Melechco Carvalho
Valdemir Melechco Carvalho
KCKarina Helena Morais Cardozo
Karina Helena Morais Cardozo
LKLuciana Kikuchi
Luciana Kikuchi
ACAline Lopes Chagas
Aline Lopes Chagas
CGCelso Francisco Hernandes Granato
Celso Francisco Hernandes Granato
Chronic hepatitis B (CHB) virus infection is a major cause of hepatocellular carcinoma (HCC), as late diagnosis is the main factor for the poor survival of patients. There is an urgent need for accurate biomarkers for early diagnosis of HCC. The aim of the study was to explore the serum lipidome profiles of hepatitis B-related HCC to identify potential diagnostic biomarkers. An ultraperformance liquid chromatography mass spectrometry (UPLC-MS) lipidomic method was used to characterize serum profiles from HCC (n = 32), liver cirrhosis (LC) (n = 30), CHB (n = 25), and healthy subjects (n = 34). Patients were diagnosed by clinical laboratory and imaging evidence and all presented with CHB while healthy controls had normal liver function and no infectious diseases. The UPLC-MS-based serum lipidomic profile provided more accurate diagnosis for LC patients than conventional alpha-fetoprotein (AFP) detection. HCC patients were discriminated from LC with 78 % sensitivity and 64 % specificity. In comparison, AFP showed sensitivity and specificity of 38 % and 93 %, respectively. HCC was differentiated from CHB with 100 % sensitivity and specificity using the UPLC-MS approach. Identified lipids comprised glycerophosphocolines, glycerophosphoserines and glycerophosphoinositols. UPLC-MS lipid profiling proved to be an efficient and convenient tool for diagnosis and screening of HCC in a high-risk population.

30 June 2022 in Journal of Proteome Research
Verified
Journal Article
Closed access
DLDebora A. Lima
Debora A. Lima
RSRodrigo A. Schuch
Rodrigo A. Schuch
JSJéssica S. Salgueiro
Jéssica S. Salgueiro
MPMaria Carolina T. Pintão
Maria Carolina T. Pintão
VCValdemir M. Carvalho
Valdemir M. Carvalho

15 August 2023 in Brain Pathology
Verified
Journal Article
Open access
AAAmanda Faria Assoni
Amanda Faria Assoni
EGErika N. Guerrero
Erika N. Guerrero
RWRené Wardenaar
René Wardenaar
DODanyllo Oliveira
Danyllo Oliveira
PBPetra L. Bakker
Petra L. Bakker
FFFloris Foijer
Floris Foijer
Amyotrophic lateral sclerosis type 6 (ALS6) is a familial subtype of ALS linked to Fused in Sarcoma (FUS) gene mutation. FUS mutations lead to decreased global protein synthesis, but the mechanism that drives this has not been established. Here, we used ALS6 patient‐derived induced pluripotent stem cells (hIPSCs) to study the effect of the ALS6 FUSR521H mutation on the translation machinery in motor neurons (MNs). We find, in agreement with findings of others, that protein synthesis is decreased in FUSR521H MNs. Furthermore, FUSR521H MNs are more sensitive to oxidative stress and display reduced expression of TGF‐β and mTORC gene pathways when stressed. Finally, we show that IFNγ treatment reduces apoptosis of FUSR521H MNs exposed to oxidative stress and partially restores the translation rates in FUSR521H MNs. Overall, these findings suggest that a functional IFNγ response is important for FUS‐mediated protein synthesis, possibly by FUS nuclear translocation in ALS6.